10%: If a patient is a candidate for a Whipple, meaning no nodes or spread of tumor at the 1-2yr interval the survival is 10%. This may change since new immunothrapeutics are being developed. It will require a vaccine which turns on humoral immunity to produce the necessary monoclonals to prevent recurrent. The vaccine has been developed for tumor specific protein and not GVAX
Answered 11/7/2014
3.6k views
7 doctors weighed in across 3 answers
A doctor has provided 1 answer
A doctor has provided 1 answer
A doctor has provided 1 answer
2 doctors weighed in across 2 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question